

PRESS RELEASE

Theranexus, which holds an exclusive license agreement for a patent from collaborative research by the CEA and Bio-Modeling Systems, has announced:

Theranexus, the CEA and Bio-Modeling-Systems sign an agreement on new therapeutic strategies for use in psychiatry

Paris, December 10, 2013: Theranexus, a biopharmaceutical company created as a CEA spin-off, has announced the signing of a licence agreement with the CEA and Bio-Modeling Systems (BMSystems). The agreement authorises the exploitation of agents capable of altering the therapeutic effect of psychotropic substances (anti-depressants, anti-psychotics, psycho-stimulants, etc.). The technology in question, born of collaborative research by the CEA and BMSystems and now licensed to Theranexus, constitutes a solid core of industrial property offering broad prospects for high-potential industrial applications.

Psychotropic medications are some of the most widely used drugs in the world, e.g. in France – where they represent 25% of prescriptions, and in the United States – where anti-depressants are the most-prescribed drugs for the 18-44 age group. In France, more than 40% of people over the age of 60 take at least one psychoactive substance per day. Yet only 30% of patients taking antidepressants describe overall improvement, whereas 70% of patients notice sexual dysfunctions. Thus, finding solutions to make these drugs safer and more effective is clearly a matter of serious consequence for public health. Theranexus focuses its activities on improving the risk benefit ratio for psychotropic medications in indications for which the medical needs remain largely unmet.

About Theranexus

Theranexus, a CEA spin-off, was created on 19 March 2013. Its mission is to design and develop drug combinations to improve the safety and effectiveness of psychiatric medications. Theranexus relies on support and assistance from the CEA's cross-disciplinary "Technologies for Health" program, the Exploitation Department within the CEA's Life Sciences Division, and CEA Investissement, which is involved in the company's strategic planning and associated with Theranexus as co-founder. Theranexus aims to develop its first product for the severe narcolepsy indication, up to Phase IIa: effectiveness for the patient. Theranexus is also continuing its efforts to develop other approaches and to strengthen its "pipeline" of candidate molecules, drawing on the expertise within the scientific environment of the CEA's Life Sciences Division.

Contact:

Franck Mouthon (CEO) – franck.mouthon@theranexus.com

Mathieu Charvériat (CSO) – mathieu.charveriat@theranexus.com

About the CEA

The French Atomic Energy and Alternative Energies Commission (CEA) is a public research organisation operating in four main areas: carbon-based energy, information and healthcare technologies, very large-scale research infrastructures (TGIR), and defence and global security. Drawing on its widely acknowledged technical expertise and excellence in fundamental research, the CEA actively participates in collaborative projects with a large number of academic and industrial partners. With 16,000 researchers and employees, the CEA plays a leading role in the European research community and its international presence is constantly growing.

The CEA's Life Sciences Division (DSV) is conducting cutting-edge research for energy and health in the fields of radiobiology, nuclear and environmental toxicology, medical imaging, large-scale biology, protein engineering, bioenergies, genomics and biotechnologies. The DSV has a very strong policy on the exploitation of its research work. The DSV is involved in life sciences strategy and resource coordination at the national level, notably in representing the CEA within the national alliance for life science and health (AVIESAN) and as a member of the competitiveness cluster MEDICEN - Paris region.

For more information: <http://www-dsv.cea.fr>

Press Contact: Coline Verneau – coline.verneau@cea.fr – +33 (0)1 64 50 14 88

About Bio-Modeling Systems (BMSystems)

Founded in 2004, Bio-Modeling Systems (BMSystems) is a pioneer company in the non-mathematical in-silico heuristic models validated in-vivo, in the field of infectious diseases, immunology, neurology, psychiatry, oncology and dermatology.

For more information: www.bmsystems.net

Contact: Manuel Géa – manuel.gea@bmsystems.net – +33 (0)6 83 06 12 72